(NMRA) Neumora Therapeutics - Overview
Stock: Depression, Agitation, Alzheimer, Schizophrenia, Amyotrophic, Parkinson
| Risk 5d forecast | |
|---|---|
| Volatility | 89.8% |
| Relative Tail Risk | -12.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.52 |
| Alpha | -9.60 |
| Character TTM | |
|---|---|
| Beta | 1.280 |
| Beta Downside | 2.142 |
| Drawdowns 3y | |
|---|---|
| Max DD | 96.89% |
| CAGR/Max DD | -0.60 |
Description: NMRA Neumora Therapeutics January 02, 2026
Neumora Therapeutics (NASDAQ: NMRA) is a clinical-stage biopharma focused on oral therapeutics that modulate central nervous system pathways, targeting major depressive disorder (MDD), dementia-related agitation, and a pipeline of neurodegenerative indications.
Its lead asset, navacaprant (NMRA-140), is a once-daily kappa-opioid receptor antagonist currently in a pivotal Phase 3 trial for MDD. The study is enrolling ~650 patients across the U.S., with a primary endpoint readout anticipated in Q4 2024. Navacaprant’s mechanism aims to address residual depressive symptoms that are not fully managed by existing serotonergic agents.
Early-stage programs include NMRA-511 (Phase 1 for Alzheimer’s-related agitation), preclinical NMRA-NMDA and NMRA-M4R for schizophrenia, NMRA-CK1d for amyotrophic lateral sclerosis, NMRA-NLRP3 for select neurodegenerative disorders, and NMRA-GCase for Parkinson’s disease. Collectively, these targets align with a $200 billion global neuro-psychiatric drug market that is expanding at ~6 % CAGR, driven by an aging population and rising mental-health awareness.
As of the most recent filing, Neumora reported cash and cash equivalents of roughly $45 million, giving it an estimated 12-month runway at its current burn rate of $10-$12 million per quarter. The company’s market capitalization hovers near $120 million, implying a price-to-cash ratio of ~2.7×, which is modest relative to peers in the CNS-focused biotech space.
For a deeper quantitative assessment, you may find ValueRay’s analyst dashboard useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -1.17 > 0.02 and ΔFCF/TA -65.22 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -1.17 > 3% & CFO -208.8m > Net Income -236.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (161.8m) vs 12m ago 1.42% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -326.5 > 6 (EBITDA TTM -243.6m / Interest Expense TTM 747.0k) |
Altman Z'' -15.00
| A: 0.85 (Total Current Assets 177.1m - Total Current Liabilities 25.8m) / Total Assets 177.8m |
| B: -6.32 (Retained Earnings -1.12b / Total Assets 177.8m) |
| C: -0.92 (EBIT TTM -243.9m / Avg Total Assets 265.2m) |
| D: -24.63 (Book Value of Equity -1.12b / Total Liabilities 45.7m) |
| Altman-Z'' Score: -47.08 = D |
What is the price of NMRA shares?
Over the past week, the price has changed by +6.53%, over one month by +16.48%, over three months by -17.83% and over the past year by +8.72%.
Is NMRA a buy, sell or hold?
- StrongBuy: 1
- Buy: 2
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NMRA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.1 | 331.1% |
| Analysts Target Price | 9.1 | 331.1% |
| ValueRay Target Price | 1.8 | -15.1% |
NMRA Fundamental Data Overview February 03, 2026
Revenue TTM = 0.0 USD
EBIT TTM = -243.9m USD
EBITDA TTM = -243.6m USD
Long Term Debt = 19.6m USD (from longTermDebt, last quarter)
Short Term Debt = 256.0k USD (from shortTermDebt, last quarter)
Debt = 523.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -128.5m USD (from netDebt column, last quarter)
Enterprise Value = 167.2m USD (338.2m + Debt 523.0k - CCE 171.5m)
Interest Coverage Ratio = -326.5 (Ebit TTM -243.9m / Interest Expense TTM 747.0k)
EV/FCF = -0.80x (Enterprise Value 167.2m / FCF TTM -208.8m)
FCF Yield = -124.9% (FCF TTM -208.8m / Enterprise Value 167.2m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 5.32m) / Revenue TTM)
Tobins Q-Ratio = 0.94 (Enterprise Value 167.2m / Total Assets 177.8m)
Interest Expense / Debt = 142.8% (Interest Expense 747.0k / Debt 523.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -192.7m (EBIT -243.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.85 (Total Current Assets 177.1m / Total Current Liabilities 25.8m)
Debt / Equity = 0.00 (Debt 523.0k / totalStockholderEquity, last quarter 132.2m)
Debt / EBITDA = 0.53 (negative EBITDA) (Net Debt -128.5m / EBITDA -243.6m)
Debt / FCF = 0.62 (negative FCF - burning cash) (Net Debt -128.5m / FCF TTM -208.8m)
Total Stockholder Equity = 207.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -89.11% (Net Income -236.3m / Total Assets 177.8m)
RoE = -113.8% (Net Income TTM -236.3m / Total Stockholder Equity 207.6m)
RoCE = -107.4% (out of range, set to none) (EBIT -243.9m / Capital Employed (Equity 207.6m + L.T.Debt 19.6m))
RoIC = -88.64% (negative operating profit) (NOPAT -192.7m / Invested Capital 217.4m)
WACC = 10.61% (E(338.2m)/V(338.7m) * Re(10.63%) + (debt cost/tax rate unavailable))
Discount Rate = 10.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.94%
Fair Price DCF = unknown (Cash Flow -208.8m)
EPS Correlation: 59.02 | EPS CAGR: 11.39% | SUE: 3.13 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.32 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.98 | Chg30d=+0.050 | Revisions Net=-1 | Growth EPS=+31.5% | Growth Revenue=+0.0%